All articles tagged with #consumer brands
Kimberly-Clark is acquiring Kenvue, the maker of Tylenol and other consumer health products, in a nearly $49 billion deal, aiming to create a global health and wellness leader amid challenges faced by Kenvue following controversial claims linking acetaminophen to autism.
Nvidia has topped the 2024 Axios Harris Poll 100 reputation rankings, becoming America's favorite brand and surpassing other notable companies like 3M, Fidelity Investments, and Apple. Nvidia's rise in public consciousness is attributed to its significant role in the AI revolution and its high market capitalization. The poll also highlighted a trend of tech companies scoring poorly on "citizenship" metrics, reflecting consumer pressure for greater social and environmental responsibility.
America's biggest consumer brands are reevaluating their price hikes as inflation subsides and consumers push back against higher prices. Companies like Kraft Heinz and Procter & Gamble have experienced a drop in volume, indicating that consumers are trading down to private labels or cutting back to save money. As shoppers hunt for bargains, brands are emphasizing value and offering sales and discounts. While overall inflation may moderate, consumer prices are not expected to see significant deflation. Companies will need to navigate the balance between volume and pricing as they face challenges to stay competitive in a disinflation era.
Synthetic biotechnology company Amyris has filed for Chapter 11 bankruptcy protection as it undergoes restructuring. The company plans to continue operating its consumer brands through retail partners and e-commerce platforms after selling them off. Amyris secured a $190 million commitment from an entity affiliated with its existing lender to support day-to-day operations. The company reported a net loss of $193.3 million in the first quarter and had engaged PwC to execute a transformation plan. Amyris estimated its assets to be between $500 million to $1 billion and liabilities from $1 billion to $10 billion.
Kenvue, the spinoff of Johnson & Johnson's consumer brand segment, debuted on the New York Stock Exchange at $25.53 per share, higher than the upsized pricing of $22 per share. The new company, which provides a valuation above $40 billion, will be the new home of brands such as Tylenol, Band-Aid, Motrin, Sudafed, and Neutrogena. Kenvue will operate with three different business segments of its own to house all the brands: self care, skin health, and beauty and essential health. J&J remains a majority stakeholder with more than 90% of shares.
Kenvue, the consumer-health spinoff of Johnson & Johnson, saw its shares jump 22% in its market debut on the New York Stock Exchange, making it the largest U.S. IPO in over a year. The company raised $3.8 billion and is valued at roughly $50 billion. Kenvue holds well-known consumer brands such as Band-Aid, Tylenol, and Listerine. The IPO marks the largest restructuring move in J&J's 135-year history, as the company aims to streamline operations and refocus on its faster-growing medical devices and pharmaceutical divisions.
Johnson & Johnson's Kenvue unit is set to have the biggest IPO since 2021, with a valuation of over $40 billion. The IPO will raise more than all other IPOs combined that have made it to market in 2023. Kenvue will hold consumer brands such as Band-Aid, Tylenol, and Listerine. J&J will continue to own about 92% of Kenvue and plans to distribute the remaining shares to its own shareholders in a deal that may come in the second half of the year.